Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Jan 19;34(8):816–824. doi: 10.1200/JCO.2015.64.3866

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2016 by American Society of Clinical Oncology

PMC Copyright notice

Fig 4. — Longitudinal trajectories of adjusted mean depressive symptom, fatigue, and sleep problem scores at baseline (T1) and at 6 months (T2) and 12 months (T3) of follow-up. Means were adjusted for age, education, time since last treatment, and chemotherapy. (A) Depressive symptoms, measured by the Beck Depression Inventory II (BDI-II). (B) Fatigue severity, measured by the Multidimensional Fatigue Symptom Inventory (MFSI); P = .11 for overall group-by-time interaction; P = .53 for group differences at T1; P = .23 for group differences at T2; and P = .09 for group differences at T3. (C) Sleep problems, measured by the Pittsburgh Sleep Quality Index (PSQI; adjusted means) by type of endocrine (endo) therapy at three time points. AI, aromatase inhibitor.